Achilles Therapeutics plc has established a research collaboration with Arcturus Therapeutics Holdings Inc. to evaluate best-in-class, self-amplifying mRNA (sa-mRNA) personalized cancer vaccines targeting clonal neoantigens.
About 50% of patients with small intestine neuroendocrine tumors (SI-NETs) have their prognosis negatively impacted by the development of mesenteric fibrosis, but the mechanisms behind these are poorly understood. In work at Sun Yat-sen University, single-cell RNA sequencing was performed on five primary tumor specimens and their corresponding adjacent nontumoral tissues.
Researchers from Iomx Therapeutics AG presented the discovery and preclinical evaluation of IOMX-0675, a novel LILRB1 and LILRB2 cross-specific antibody being developed for the treatment of solid tumors.
Owkin Inc. has in-licensed OKN-4395 (ACT-1002-4391), a highly selective and potent dual inhibitor of prostanoid receptors EP2 and EP4, from Idorsia Ltd.
Researchers from Novartis AG published preclinical data for the novel Werner syndrome ATP-dependent helicase (WRN) inhibitor, HRO-761, being developed for the treatment of microsatellite instability (MSI)-high cancers.
The world’s largest and most comprehensive repository of somatic mutations found in cancer is celebrating its 20th birthday by adding 307,000 new genomic variants to its 24 million-strong database. With somatic mutations being the main drivers of tumor development, the Catalogue of Somatic Mutations in Cancer (COSMIC) is firmly established as a source of potential drug targets, for the discovery and validation of biomarkers associated with prognosis, treatment response and patient outcomes, and as a resource for characterizing the mutational landscape of individual tumors.
Prologue Medicines Inc. has launched to develop therapeutics created from the viral proteome, which are proteins produced across all viruses. It’s a newer twist on harnessing the power of the proteins that regulate biology. The company was founded on the premise of peering beyond the human proteome to see if there were viral proteins that could become therapeutics, Theonie Anastassiadis, Prologue’s founding president, told BioWorld.
Kayothera Inc. has described aldehyde dehydrogenase (ALDH) inhibitors reported to be useful for the treatment of cancer, type 2 diabetes, male contraception and metabolic disease.
Tuojie Biotech (Shanghai) Co. Ltd. has divulged cyclin-dependent kinase 7 (CDK7) inhibitors reported to be useful for the treatment of autoimmune diseases, cancer, infections and inflammatory disorders.
Kymera Therapeutics Inc. has synthesized proteolysis targeting chimera (PROTAC) compounds comprising a DDB1- and CUL4-associated factor 1 (DCAF1) binding moiety covalently linked to a bromodomain-containing protein 4 (BRD4; HUNK1) targeting moiety.
RSS
